Skip to Main Content

Author Details

Li Li
Johns Hopkins University School of Medicine
2004
32
20
PMIDPaper TitleJournal TitlePublished Year
37147424NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.Leukemia2023
37147424NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.Leukemia2023
34024909FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.Signal Transduct Target Ther2021
33914060Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.Blood Adv2021
34024909FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.Signal Transduct Target Ther2021
34589716A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.Blood Cancer Discov2021
33914060Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.Blood Adv2021
34589716A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.Blood Cancer Discov2021
30975911FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.Haematologica2019
30975911FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.Haematologica2019
30450160Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in mice.Oncotarget2018
30450160Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in mice.Oncotarget2018
30250637Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.Oncotarget2018
30250637Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.Oncotarget2018
27748370DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.Leukemia2017
28923853Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.Cancer Res2017
28077790FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Oncotarget2017
27748370DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.Leukemia2017
28077790FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Oncotarget2017
28923853Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.Cancer Res2017
27103744All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Blood2016
27103744All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Blood2016
27636998Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.Oncotarget2016
27636998Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.Oncotarget2016
26360610POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.Oncotarget2015
26360610POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.Oncotarget2015
24184354NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.Exp Hematol2014
25333254Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.Oncotarget2014
24408321TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Blood2014
24184354NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.Exp Hematol2014
25060518FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Cancer Res2014
25333254Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.Oncotarget2014
25060518FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Cancer Res2014
24408321TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Blood2014
22858906Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Leukemia2013
22858906Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Leukemia2013
24255108FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.Proc Natl Acad Sci U S A2013
23294096MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.Br J Haematol2013
24255108FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.Proc Natl Acad Sci U S A2013
23294096MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.Br J Haematol2013
22323452Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.Blood2012
22927251Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Blood2012
22958930FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.Cell Stem Cell2012
22323452Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.Blood2012
22958930FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.Cell Stem Cell2012
22927251Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Blood2012
21228325Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.Blood2011
21228325Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.Blood2011
21908433Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.Blood2011
21908433Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.Blood2011
  • 1 - 50 of 64

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 0
Ashok Kumar Jayavelu
German Cancer Research Center (DKFZ)
Career Start Year 2014
Number of shared co-authors 0
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2010
Number of shared co-authors 0
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Catherine C Smith
University of California San Francisco
Career Start Year 2009
Number of shared co-authors 1
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 0
Vadym Zaberezhnyy
University of Colorado Anschutz Medical Campus
Career Start Year 2009
Number of shared co-authors 0
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 0
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 0
Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2004
Number of shared co-authors 0
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 1
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 0
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 0
Shinichiro Takahashi
Tohoku Medical and Pharmaceutical University Hospital.
Career Start Year 1998
Number of shared co-authors 0
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 0
Michael W Deininger
University of Utah Huntsman Cancer Institute
Career Start Year 1997
Number of shared co-authors 0
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 0
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 1
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 0
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 1
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 0
Benjamin S Braun
Benioff Children's Hospitals, University of California san francisco
Career Start Year 1992
Number of shared co-authors 0
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 0
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 2
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Career Start Year 1987
Number of shared co-authors 6
Brian J Druker
Oregon Health & Science University
Career Start Year 1978
Number of shared co-authors 1

Collaborators

Donald Small
Johns Hopkins University School of Medicine
Co-authored papers 31
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 14
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 9
Obdulio Piloto
Entopsis Inc.
Co-authored papers 3
Kyu-Tae Kim
Ajou University
Co-authored papers 3
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Co-authored papers 2
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Co-authored papers 2
Curt I Civin
Center for Stem Cell Biology & Regenerative Medicine and.
Co-authored papers 1
Peili Chen
University of Chicago
Co-authored papers 1
Xiaobing Yu
Heidelberg University
Co-authored papers 1
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Linzhao Cheng
Johns Hopkins University School of Medicine
Co-authored papers 1
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Kristin Baird
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Ian M Kaplan
Adaptive Biotechnologies Corp
Co-authored papers 1
Susan R Davis
Co-authored papers 1
Sean Davis
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
David M Loeb
Children's Hospital at Montefiore.
Co-authored papers 1
Zhaohui Ye
Center for Biologics Evaluation and Research
Co-authored papers 1
Christine A Pratilas
Johns Hopkins University School of Medicine
Co-authored papers 1
Release 1.2